AbbVie Inc (ABBV)vsChina SXT Pharmaceuticals Inc (SXTC)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
SXTC
China SXT Pharmaceuticals Inc
$2.56
+32.64%
HEALTHCARE · Cap: $1.19M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 5657224% more annual revenue ($64.39B vs $1.14M). ABBV leads profitability with a 9.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
SXTC
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Margin of Safety
+18.9%
Fair Value
$3.07
Current Price
$2.56
$0.51 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Conservative balance sheet, low leverage
Earnings expanding 42.6% YoY
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -50.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : SXTC
The strongest argument for SXTC centers on Price/Book, Debt/Equity, EPS Growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : SXTC
The primary concerns for SXTC are Market Cap, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
SXTC carries more volatility with a beta of 1.84 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 38/100) and 10.2% revenue growth. SXTC offers better value entry with a 18.9% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
China SXT Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · China
China SXT Pharmaceuticals, Inc., a pharmaceutical company, is engaged in the research, development, manufacture, marketing and sale of Traditional Chinese Medicine Tablets (TCMP) in China. The company is headquartered in Taizhou, China.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?